Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,060 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fibrosis, Pulmonary Clear all
Recruiting No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

NCT03502902
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HEC 68498, Placebo
Drug
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center

NCT03052231
View directory record Official record
Conditions
Medication Adherence, Cystic Fibrosis
Interventions
caremessage
Device
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
4 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

NCT01879228
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Jun 25, 2026, 10:48 PM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

NCT07201922
View directory record Official record
Conditions
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Interventions
Nerandomilast, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients

NCT01784419
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ivacaftor, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

NCT01265888
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Geno LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jun 25, 2026, 10:48 PM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

NCT01509339
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Vancomycin
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Effects of Innovative Aerobic Exercise Training in Cystic Fibrosis

NCT04543929
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
exercise
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Jun 25, 2026, 10:48 PM EDT
Withdrawn Not applicable Interventional

The Effectiveness of the Jamboxx Respiratory Therapy Device: Study 2

NCT03522480
View directory record Official record
Conditions
Cystic Fibrosis in Children
Interventions
Jamboxx Respiratory Therapy Device, Autogenic Draining Training
Device · Other
Lead sponsor
My Music Machines Inc.
Industry
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00125385
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GC1008
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

NCT05437120
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Jun 25, 2026, 10:48 PM EDT
Completed No phase listed Observational

Genetic Modifiers of Cystic Fibrosis: Sibling Study

NCT00037778
View directory record Official record
Conditions
Lung Diseases, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 100 Years
Enrollment
3,459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

NCT01442779
View directory record Official record
Conditions
Respiratory Tract Diseases, Lung Diseases, Lung Diseases, Interstitial, Pulmonary Fibrosis
Interventions
Interferon alpha oral lozenge
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional

Project 2 Airway Potential Hydrogen (pH) in Asthma

NCT03617718
View directory record Official record
Conditions
Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Interventions
Glycine Buffer
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients

NCT01822197
View directory record Official record
Conditions
Depression, Cystic Fibrosis
Interventions
Phototherapy
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Jun 25, 2026, 10:48 PM EDT
Active, not recruiting No phase listed Observational

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Integrating Supportive Care in Cystic Fibrosis

NCT02668575
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Supportive Care Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Jun 25, 2026, 10:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor

NCT03367494
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Measurement of Sweat Chloride and Sweat Bromide
Diagnostic Test
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Jun 25, 2026, 10:48 PM EDT
Completed No phase listed Observational

The Sinonasal Cavity as a Reservoir for Upper Airway Bacterial Development

NCT03016689
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
7 Days to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study

NCT06350461
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Results available

A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.

NCT00377741
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Jun 25, 2026, 10:48 PM EDT
Completed No phase listed Observational Results available

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05870956
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
66 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Milton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jun 25, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Project UPLIFT to Reduce Anxiety and Depression in CF Patients

NCT03139266
View directory record Official record
Conditions
Cystic Fibrosis, Anxiety, Depression
Interventions
UPLIFT, Treatment as usual
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
13 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Jun 25, 2026, 10:48 PM EDT